NCT05954871
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05954871
Title Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Genentech, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS

Facility Status City State Zip Country Details
SCRI Oncology Partners Nashville Tennessee 37203 United States Details
START South Texas Accelerated Research Therapeutics-San Antonio San Antonio Texas 78229 United States Details
Border Medical Oncology Wodonga New South Wales 3690 Australia Details
St Vincent's Hospital Melbourne Fitzroy Victoria 3065 Australia Details
Seoul National University Hospital Seoul 03080 South Korea Details
Asan Medical Center Seoul 05505 South Korea Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field